



# IMI rules and procedures

**Magali Poinot, Legal Manager**

13 January 2015 • IMI 2 Open Info Day • Barcelona

# Outline

1. Participation rules
2. Funding rules
3. Intellectual Property rules
4. From evaluation to grant award
5. More information

# A single set of rules



EU Financial  
Regulation

Specific rules  
for  
participation

- Covering all H2020 research and innovation actions
- Adaptability where needed:
  - Entities eligible for funding
  - IP

# Participation rules

# Attracting stakeholders

**Any legal entity carrying out work relevant to the Call objectives may participate in applicant consortia, regardless of its place of establishment.**

# Who is eligible for funding?

- Academic institutions
- Small & medium-sized enterprises (SMEs)
- Mid-sized enterprises ( $\leq$  €500m)
- Non-profit organisations e.g. research organisations, patient organisations, NGOs, public bodies, intergovernmental organisations etc.

Established in:

- **EU Member State**
- **Associated Country**

***Other countries:***  
***No funding unless***  
***- participation deemed***  
***essential by IMI for carrying out***  
***the action***  
***- foreseen in the **Annual Work Plan*****

# Simplified conditions for participation

- **Minimum conditions for standard collaborative actions**  
Research and Innovation Actions: At least **three** legal entities  
Coordination and Support Actions: At least **one** legal entity  
each established in a different Member State or  
an associated country
- **Additional conditions**  
In the annual work plan (and Call documents)

# Funding rules



# One single funding rate per project

**One project = One rate**

**For all beneficiaries and all activities**

**Defined in the annual work plan/Call documents:**


- Up to 100% of the eligible costs
- Limited to a maximum of 70% for innovation projects (exception for non-profit organisations - maximum of 100%)

# One single indirect cost model

**Single  
model:  
25 % Flat  
Rate**

# A more attractive funding model

## An example

 <i>Majority of beneficiaries</i>	Direct costs	Indirect costs	Total costs	% EU contribution	EU contribution
Flat-rate (20%) (or actual)	100	20	120	75%	€90

HORIZON 2020	Direct costs	Indirect costs	Total costs	% IMI2 contribution	IMI2 contribution
100/25 Funding	100	25	125	100%	€125

# EFPIA and Associated Partners contribution

- EFPIA companies
- Other industries and partners (= Associated Partners to IMI2) *New!*
  - In-kind (actual direct and indirect costs or average FTE) + cash contributions
  - Based on the usual management principles and accounting practices
  - Contributions from affiliated entities as part of in-kind

When relevant to IMI2 objectives: up to 30% non-EU in-kind contribution

# Intellectual property rules

# IMI's IP policy allows unprecedented levels of sharing

Companies pooling legacy toxicity data

European platform for antibiotic development

The IMI logo consists of the lowercase letters 'imi' in a bold, green, sans-serif font. The letters are enclosed within a dark blue oval shape that has two small black dots at the top and bottom, resembling a stylized orbit or a molecular structure.


imi

Companies pooling & sharing old trial data


European Lead Factory compound collection

Project partners validate each other's findings

# One set of rules for multiple interests



# Background vs. Results





# Access Rights conditions


Access rights granted by a beneficiary to/on	Background (necessary and identified)	Results	Sideground
<b>Beneficiaries for completion of the action</b>	<b>Royalty-free</b>	<b>Royalty-free</b>	N.A.
<b>Beneficiaries and affiliates for Research Use</b>	<b>Fair &amp; reasonable terms</b> for background needed for using the results	<b>Fair &amp; reasonable terms</b>	N.A.
<b>Third Parties for Research Use after the action</b>	<b>Fair &amp; reasonable terms</b> for background needed for using the results	<b>Fair &amp; reasonable terms</b>	N.A.
<b>Beneficiaries and affiliates or Third Parties for Direct Exploitation</b>	To be negotiated	To be negotiated	N.A.

Based on previous experience



# From evaluation to grant award

# A single set of evaluation criteria



- Two-stage evaluation: only “Excellence” and “Impact” considered at stage 1
- Thresholds and weighting in the Call documents
- Minimum of 3 independent experts (possibility of 2 in a two-stage process)

**NEW** Each proposal evaluated 'as it is', not as 'what could be'.

# Keeping the momentum

A maximum Time To Grant of 8 months from the submission of the full proposal

Fast track process may be foreseen in the annual work plan / Call documents

**5 (2) months**  
for informing applicants  
on scientific evaluation

**3 (2) months**  
for signature of grant  
agreement

***NEW*** Legal entity validated in parallel

# Simplified model Grant Agreement



*Signed between IMI2  
JU and coordinator only  
(no more managing  
entity)*

*Accession form by the  
other beneficiaries*

Core text

Special  
clauses

General  
conditions  
*Annex II*

Specific  
provisions  
*Annex III*

# Consortium agreement

- Contractual arrangement **between all participants** to set out their rights and obligations, especially governance, liability and IPR
- Shall comply with the IMI2 model Grant Agreement
- Before the signature of the grant agreement with the IMI Office
- **To be adapted to the specific needs of each IMI action!**

# Reference documents

- **H2020 Rules for Participation**
- **IMI2 Delegated Regulation**
- **IMI2 Call Documents**
- **IMI2 model Grant Agreement (revised)**
- **IMI2 annotated Grant Agreement (soon)**

[www.imi.europa.eu/content/documents](http://www.imi.europa.eu/content/documents)



**Thank you**

[xxx@imi.europa.eu](mailto:xxx@imi.europa.eu)

[www.imi.europa.eu](http://www.imi.europa.eu)

 [@IMI\\_JU](https://twitter.com/IMI_JU)